Home › Amgen Submits BLA for Investigational BiTEA Immunotherapy Blinatumomab
 

Keywords :   


Amgen Submits BLA for Investigational BiTEA Immunotherapy Blinatumomab

2014-09-23 07:04:12| Biotech - Topix.net

THOUSAND OAKS, Calif., Sept. 22, 2014 /PRNewswire/ -- Amgen today announced submission of a Biologics License Application to the U.S. Food and Drug Administration seeking approval for its investigational bispecific T cell engager antibody construct, blinatumomab.

Tags: bla submits investigational immunotherapy

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
24.11S
24.11
24.115
24.11SR
24.11 RC24.4.5
24.11115+128717dz
24.11lavaSUKALA 3
24.11508A
More »